Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2679-2683

  Huland, Edith ^a   Heinzer, Hans ^a   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Inhalation; Interferon ; Interleukin 2; Pulmonary metastases; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT;

ADMINISTRATION, INHALATION; ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0032781576     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Maldazys JD and deKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol 136: 376-379, 1986.
2. Patel NP and Lavengood RW: Renal-cell carcinoma: natural history and results of treatment. J Urol 119: 722, 1978.
3. Thrasher JB and Paulson DF: Prognostic factors in renal cancer. Urol Clin N Amer 20: 247-262, 1993.
4. DeKernion JB: Treatment of advanced renal-cell carcinoma -traditional methods and innovative approaches. J Urol 130: 2, 1983.
5. Goepel M and Rübben H: Adjuvant therapy in renal cancer. World J Urol 9: 232-236, 1991.
6. Atzpodien J, Körfer A, Franks CR, et al: Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335: 1509-1512, 1990.
7. Figlin RA, Belldegrun A, Moldawer N et al: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2a: an active outpatient regimen in metastic renal-cell carcinoma. J Clin Oncol 10: 404-412, 1992.
8. Hänninen EL, Kirchner H and Atzpodien J: Interleukin-2 based home therapy of metastic renal-cell carcinoma: risk and benefits in 215 consecutive single institution patients. J Urol 155: 19-25, 1996.
9. Hofmockel G, Langer W, Theiss M, et al: Immunochemotherapy for metastic renal-cell carcinoma using a regimen of interleukin-2, interferon-a and 5-Fluorouracil. J Urol 156: 18-21, 1996.
10. Lümmen G, Goepel M, Möllhoff S et al: Phase II study of interferon-γ versus interleukin-2 and interferon-α2b in metastatic renal cell carcinoma. J Urol 155: 455-458, 1996.
11. Rosenberg SA, Lotze MT, Muul LM et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316: 889-897, 1987.
12. Sosman JA, Kohler PC, Hank JA et al: Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and adition of indomethacin. J Natl Cancer Inst 80: 1451-1461, 1988.
13. West WH, Tauer KW, Yanelli JR et al: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl J Med 316: 898-905, 1987.
14. Lee RE, Lotze MT, Skibber JM et al: Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7: 7-20, 1989.
15. Rosenberg SA, Yang JC, Topalian SL et al: Treatment of 283 consecutive patients with metastic melanoma or renal-cell carcinoma using high-dose bolus interleukin-2. JAMA 271: 907-913, 1994.
16. Rosenstein M, Ettinghausen SE and Rosenberg SA: Extravasation of intravascular fluid mediated by systemic administration of recombinant interleukin 2. J Immunol 137: 1735-1742, 1986.
17. Dillmann RO, Church C, Oldham RK et al: Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71: 2358-2370, 1993.
18. Parkinson DR, Abrams JS, Wiernik PH et al: Interleukin-2 therapy in patients with metastic malignant melanoma, a phase II study. J Clin Oncol 8: 1650-1656, 1990.
19. Rosenberg SA, Lotze MT, Yang JC et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patient. Annals of Surgery 210: 474-485, 1989.
20. Huland E, Falk B, Huebner D et al: In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors. J Cancer Res Clin Oncol: 285-290, 1995.
21. Huland E and Huland H: Local continuous high dose interleukin-2. A new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49: 5469-5474, 1989.
22. Aulitzky WE, Kessler M, Wilhelm M, et al: Aerosolized natural interleukin-2 for treatment of advanved malignancy: Results of a phase I trial. Ann Hematol 66 [Suppl 2]: A109, 1993 (abstr)
23. Huland E, Heinzer H and Huland H: Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon a in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 120: 221-228, 1994.
24. Huland E, Huland H and Heinzer H: Interleukin-2 by inhalation: local therapy for metastatic renal-cell carcinoma. J Urol 147: 344-348, 1992.
25. Kaiser U, Pflüger K-H, Havemann K, et al: Inhalation therapy with interleukin 2 in bronchio alveolar carcinoma. Onkologie 18 (Suppl 2): 94, 1995 (abstr)
26. Knobloch R: Kombinierte Immun-/Chemotherapie des fortgeschrittenen Nierenzellkarzinoms mit Interleukin-2, Interferon alpha 2a, und Vinblastin. Presented at the 37. Tagung Südwestdeutsche Gesellschaft für Urologie, 1996
27. Kelling S, Heinzer H, Huland E, et al: In vitro model for nebulizing interleukin-2: quantitative evaluation and biological activity of three different preparations of nebulized IL-2. Immunobiology 196, 1-3: 110-111, 1996 (abstr)
28. Zissel G, Aulitzky WE, Lorenz J, et al: Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol Immunother 42: 122-126, 1996.
29. Elson PJ, Witte RS and Trump DL: Prognostic factors for survival in patients with recurrent or metastic renal-cell carcinoma. Cancer Res 48: 7310-7313, 1988.
30. Lissoni P, Barni S, Ardizzoia A, et al: Prognostic factors of clinical response to subcutaneous immunotherapy with interleukin-2, in patients with metastatic renal carcinoma. Oncology 51: 59-62, 1994.
31. Mani S, Todd MB, Katz K et al: Prognostic factors of survival in patients with metastatic renal cell cancer treated with biological modifiers. J Urol 154: 35-40, 1995.
32. Palmer PA, Vinke J, Philip T et al: Prognostic factors of survival in patients with advanced renal-cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475-480, 1992.
33. Belldegrun A, Franklin J, Dorey F, et al: Long term survival of 181 patients with metastatic renal cell carcinoma treated with IL-2 based immunotherapy with/without tumor infiltrating lymphocytes. J Urol 155: 656A, 1996 (abstr)